Novartis: positive results in psoriatic arthritis

(CercleFinance.com) - On Thursday Novartis unveiled phase III results showing that Cosentyx, its treatment for rheumatism, reduced inflammatory pain associated with psoriatic arthritis.


According to the results of a study conducted over 12 weeks, Cosentyx generated a "significant" response in synovitis (joint inflammation) compared with placebo, the Swiss laboratory said in a statement.

Cosentyx, a human monoclonal antibody, neutralises interleukin-17A, a protein that plays a key role in the development of a number of immune diseases.


Copyright (c) 2020 CercleFinance.com. All rights reserved.